Aaron Edelheit - Investing in Cannabis: The Next Great Investment Opportunity | #541

Episode Summary

Executive Summary: The episode centers on Aaron Edelheit’s bullish case for cannabis as a long-duration investing theme driven by low institutional participation, legalization momentum, and substitution away from alcohol, opioids, and other more toxic substances. He argues the industry is moving from chaos to operational excellence, with select companies showing strong unit economics and consolidation potential. A major focus is hemp-derived THC beverages, which he sees as a fast-emerging alcohol replacement category with major distribution advantages.

Main Topics: Why cannabis remains an attractive investing niche (Priority: 5/5): Edelheit argues cannabis is compelling because institutional investors are largely absent due to federal illegality, leaving little competition and significant informational inefficiency for diligent investors. Legalization, rescheduling, and federal reform (Priority: 5/5): The conversation explains why federal change is slow, how state-by-state legalization created a fragmented market, and why rescheduling from Schedule I to Schedule III could unlock capital and legitimacy even if banking and listings remain uncertain. Cannabis as a substitute for alcohol, opioids, and other drugs (Priority: 5/5): Edelheit frames cannabis as a 'great replacement' for more harmful substances, citing reduced drinking, fewer alcoholics in Canada after legalization, lower workers' comp claims, and personal use for insomnia. Operational excellence and cultivation moats (Priority: 5/5): He stresses that successful cannabis investing requires understanding cultivation, quality control, and cost structure; growing high-quality flower is difficult, and scale can be a disadvantage if not paired with precision agriculture and consistency. Valuation, mean reversion, and long-term thematic investing (Priority: 4/5): Cannabis now combines structural growth with cheap valuations and battered sentiment, making it attractive under a patient, small-position, add-on-on-dips framework over a 10+ year horizon. Hemp beverages as a breakout category (Priority: 5/5): Edelheit highlights hemp-derived THC beverages as an underappreciated, federally legal alcohol-replacement category with strong product-market fit, broad distribution potential, and rapid growth in states like Minnesota. Portfolio construction and market structure (Priority: 3/5): He discusses investing across public MSOs, Canadian names, special situations, and adjacent sectors like alcohol and tobacco, while noting ETF mechanics such as securities-lending revenue can matter materially for investors.

Key Arguments: Cannabis attracts few institutional investors because federal illegality keeps nearly all mainstream capital out, creating an opportunity for specialized research and patience. The real investment edge is not just legalization headlines; it is understanding unit economics, supply chains, and which operators can consistently grow quality product at low cost. Cannabis is replacing more harmful substances rather than serving as a gateway drug; he argues the data support substitution effects into alcohol, opioids, and pharmaceuticals. Federal reform is slow because the U.S. system is designed to resist change, and cannabis has historically been politicized rather than treated as a policy priority. Rescheduling would be a major signal and likely bring more capital into the sector, even though its exact effects on banking and listings remain uncertain. High-end cannabis is a difficult, fast-fashion-like agricultural business where genetics, quality control, and mold/pest management matter enormously. Cannabis now looks more attractive than in 2019 because it combines structural growth, cheap valuations, and a powerful mean-reversion setup after a brutal bear market. Hemp THC beverages may be the most important near-term growth story because they can be sold through existing alcohol channels and already show meaningful share capture in some markets. The industry’s future likely includes consolidation and convergence with alcohol/tobacco players, who have strong incentives to participate as the category matures. Investors should think in decades, not quarters: these types of themes often take much longer to play out than consensus expects.

Data Points: Institutional participation in cannabis: 99% to 99.9% not involved - Edelheit argues almost all institutional investors remain absent due to federal illegality. US cannabis market size: ~$30 billion - Current size of the state-legal U.S. cannabis market as cited in the discussion. US alcohol market size: ~$260 billion to $262 billion - Used as a comparison for the long-term addressable market if cannabis beverages substitute for alcohol. Workers' comp claims: Down when a state legalizes cannabis - Presented as evidence that cannabis replaces more harmful substances people use to get through the day. Alcohol deaths in the US: 178,000 annually - Edelheit cites this CDC-linked figure to contrast alcohol’s harm with cannabis. Children affected by alcohol: 4,000 annually - Used in his broader argument about alcohol’s societal cost. Annual economic damage from alcohol: $250 billion - Referenced as the CDC-estimated cost of alcohol to the economy. Canada alcoholics after legalization: 250,000 to 400,000 fewer - Edelheit says cannabis legalization in Canada reduced alcoholism. Cannabis beverage share in Minnesota liquor stores: 10% then 15% to 25% in Minneapolis - He cites rapid growth of hemp THC beverages in liquor stores as evidence of product-market fit. Cannabis flower price in California: $600 to $700 per pound - Example of lower-cost production in a competitive outdoor market. Cannabis flower price in New Jersey: ~$3,500 per pound - Illustrates extreme price dispersion caused by state-by-state market fragmentation. California cultivation capacity shift: 26 million square feet left in the past two years - Used to show how supply exited the market and helped stabilize prices. Glasshouse gross margin: 50%+ - Cited as evidence that some operators can earn software-like margins despite being agricultural businesses. Glasshouse capacity utilization: ~40% - Shows room for growth even before full deployment of massive greenhouse assets. Target cultivation temperatures: Average 72 degrees - Describes the favorable climate advantage of Glasshouse's California greenhouse location. Low-dose hemp beverage THC example: 5 to 10 mg THC - Explained as a small dose relative to a 330g can and within the hemp legal framework. Cannabis industry growth: Nearly 30% a year - Referenced from prior thematic research as a long-term growth assumption. Adoption timeframe: 10+ year holding period - Edelheit’s suggested time horizon for thematic cannabis investing. Monster Energy stock performance: ~42,000% in 30 years - Used to illustrate the power of beverage categories over long periods. Celsius stock performance: ~5,000% to 6,000% - Another example of strong beverage/category equity performance.

Pivotal Quotes: "Cannabis is the great replacement." — Aaron Edelheit: He frames cannabis as a substitute for more toxic substances and a major source of long-term demand. "The flower that you smoke, flower where all the value is, it has no protection." — Aaron Edelheit: Used to explain why cultivation quality and disease control are critical and why growing cannabis is hard. "It's a fast-fashion business." — Aaron Edelheit: Describing high-end cannabis cultivation, where genetics and consumer preferences change quickly.

Implications: Cannabis may be entering a new phase: rescheduling, consolidation, and beverage-led expansion could attract more capital and reward patient investors. The best opportunities likely lie in operators with real operational advantages and in hemp beverage distribution.